论文部分内容阅读
目前,国内辅助生殖技术中控制性超促排卵(controlled ovarian hyperstimulation,COH)仍以促性腺激素释放激素激动剂(gonadotropin releasing hormone agonist,GnRH-a)长方案为主,但GnRH-a长方案中的大剂量、长时间的促性腺激素(gonadotropin,Gn)暴露对卵泡的生长、卵子的发育不利.20世纪90年代,促性腺激素释放激素拮抗剂(gonadotropin releasing hormone antagonist,GnRH-A)开始用于人类辅助生殖技术(assisted reproductive technology,ART).GnRH-A通过与垂体促性腺激素释放激素(gonadotropin releasing hormone,GnRH)受体结合,有效抑制早发黄体生成素(luteinizing hormone,LH)峰,具有起效快、作用时间短、停药后垂体恢复迅速等特点,然而其在不同卵巢功能患者超排中的应用尚存在争议.本文对GnRH-A在ART中的临床应用作一综述.“,”Gonadotropin-releasing hormone agonists (GnRH-a)are widely used in controlled ovarian hyperstimulation (COH) at present in China.However,more and more studies show that long-term and large dose administration of GnRH-a would have an adverse effects on oocytes.Gonadotropin-releasing hormone antagonists (GnRH-A) have been used in human assisted reproduction technology (ART) since 1990s.As a competitive inhibitor of gonadotropin-releasing hormone (GnRH) receptors,GnRH-A can prevent the premature luteinizing hormone (LH) surge during COH,and GnRH-A has the advantages of fast action,short action duration and quick pituitary recovery.But it is controversial to use GnRH-A in patients with different ovarian responses.In this article,we will review the clinical application of GnRH-A in ART,focusing on its use in patients with different ovarian function.